Role of SUMOylation in Full Antiestrogenicity
- 1 October 2012
- journal article
- research article
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 32 (19) , 3823-3837
Abstract
The selective estrogen receptor downregulator (SERD) fulvestrant can be used as second-line treatment for patients relapsing after treatment with tamoxifen, a selective estrogen receptor modulator (SERM). Unlike tamoxifen, SERDs are devoid of partial agonist activity. While the full antiestrogenicity of SERDs may result in part from their capacity to downregulate levels of estrogen receptor alpha (ERα) through proteasome-mediated degradation, SERDs are also fully antiestrogenic in the absence of increased receptor turnover in HepG2 cells. Here we report that SERDs induce the rapid and strong SUMOylation of ERα in ERα-positive and -negative cell lines, including HepG2 cells. Four sites of SUMOylation were identified by mass spectrometry analysis. In derivatives of the SERD ICI164,384, SUMOylation was dependent on the length of the side chain and correlated with full antiestrogenicity. Preventing SUMOylation by the overexpression of a SUMO-specific protease (SENP) deSUMOylase partially derepressed transcription in the presence of full antiestrogens in HepG2 cells without a corresponding increase in activity in the presence of agonists or of the SERM tamoxifen. Mutations increasing transcriptional activity in the presence of full antiestrogens reduced SUMOylation levels and suppressed stimulation by SENP1. Our results indicate that ERα SUMOylation contributes to full antiestrogenicity in the absence of accelerated receptor turnover.Keywords
This publication has 99 references indexed in Scilit:
- The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacyBiochemical Pharmacology, 2011
- A Novel Proteomics Approach to Identify SUMOylated Proteins and Their Modification Sites in Human CellsMolecular & Cellular Proteomics, 2011
- The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognitionNature Reviews Molecular Cell Biology, 2010
- SUMO E3 ligase activity of TRIM proteinsOncogene, 2010
- PML Nuclear BodiesCold Spring Harbor Perspectives in Biology, 2010
- SUMOylation Attenuates the Function of PGC-1αJournal of Biological Chemistry, 2009
- Role of SUMO in RNF4-mediated Promyelocytic Leukemia Protein (PML) DegradationJournal of Biological Chemistry, 2009
- FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific TranscriptionCell, 2008
- A role for SUMO modification in transcriptional repression and activationBiochemical Society Transactions, 2007
- Ubiquitin and SUMO systems in the regulation of mitotic checkpointsTrends in Biochemical Sciences, 2006